221 related articles for article (PubMed ID: 30187599)
1. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D.
Lampertico P; Brunetto MR; Craxì A; Gaeta GB; Rizzetto M; Rozzi A; Colombo M;
J Viral Hepat; 2019 Jan; 26(1):118-125. PubMed ID: 30187599
[TBL] [Abstract][Full Text] [Related]
2. Add-on pegylated interferon augments hepatitis B surface antigen clearance
Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
[TBL] [Abstract][Full Text] [Related]
3. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
4. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
5. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
[TBL] [Abstract][Full Text] [Related]
6. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
Chi H; Hansen BE; Guo S; Zhang NP; Qi X; Chen L; Guo Q; Arends P; Wang JY; Verhey E; de Knegt RJ; Xie Q; Janssen HLA
J Infect Dis; 2017 Apr; 215(7):1085-1093. PubMed ID: 28329061
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study.
Charatcharoenwitthaya P; Sukeepaisarnjaroen W; Piratvisuth T; Thongsawat S; Sanpajit T; Chonprasertsuk S; Jeamsripong W; Sripariwuth E; Komolmit P; Patcharatrakul T; Boonsirichan R; Bunchorntavakul C; Tuntipanichteerakul S; Tanwandee T;
J Gastroenterol Hepatol; 2016 Nov; 31(11):1874-1881. PubMed ID: 26997582
[TBL] [Abstract][Full Text] [Related]
9. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir - A prospective study.
Chan HLY; Chan FWS; Hui AJ; Li MKK; Chan KH; Wong GLH; Loo CK; Chim AML; Tse CH; Wong VWS
J Viral Hepat; 2019 Jan; 26(1):126-135. PubMed ID: 30187604
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Gish RG; Lau DT; Schmid P; Perrillo R
Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
[TBL] [Abstract][Full Text] [Related]
11. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.
Liaw YF; Jia JD; Chan HL; Han KH; Tanwandee T; Chuang WL; Tan DM; Chen XY; Gane E; Piratvisuth T; Chen L; Xie Q; Sung JJ; Wat C; Bernaards C; Cui Y; Marcellin P
Hepatology; 2011 Nov; 54(5):1591-9. PubMed ID: 22045673
[TBL] [Abstract][Full Text] [Related]
12. Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection.
Rosenthal P; Ling SC; Belle SH; Murray KF; Rodriguez-Baez N; Schwarzenberg SJ; Teckman J; Lin HS; Schwarz KB;
Hepatology; 2019 Jun; 69(6):2326-2337. PubMed ID: 30318613
[TBL] [Abstract][Full Text] [Related]
13. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
14. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
15. [HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)-ide analog: new switch study].
Hu P; Shang J; Zhang WH; Gong GZ; Li YG; Chen XY; Jiang JN; Xie Q; Dou XG; Sun YT; Li YF; Liu YX; Liu GZ; Ma DW; Chi XL; Tang H; Li XO; Xie Y; Chen XP; Jiang JJ; Zha P; Hou JL; Gao ZL; Fan HM; Ding JG; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2018 Oct; 26(10):756-764. PubMed ID: 30481882
[No Abstract] [Full Text] [Related]
16. Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs.
Bao X; Guo J; Xiong F; Qu Y; Gao Y; Gu N; Lu J
Int J Infect Dis; 2020 Jul; 96():562-566. PubMed ID: 32474201
[TBL] [Abstract][Full Text] [Related]
17. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy.
Barone M; Iannone A; Di Leo A
World J Gastroenterol; 2014 Jul; 20(26):8722-5. PubMed ID: 25024631
[TBL] [Abstract][Full Text] [Related]
18. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
19. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
[TBL] [Abstract][Full Text] [Related]
20. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
